Molecular & Digital Pathology

We have developed, pioneered and disseminated several techniques in molecular pathology. Those include multiplexed immunohistochemistry and in situ hybridization, ex vivo tumor organotypic culture, to investigate antitumoral pharmacological properties that preserves the original cancer microenvironment, the discovery of p63 as a marker used in prostate cancer diagnosis. I contributed to the generation of the landscape of genomic alterations in prostate cancer as a co-leader of the Prostate TCGA Consortium and, more recently, the molecular landscape of tumor stroma in prostate cancer progression by scRNASeq. We developed a method to perform metabolic profiling in formalin-fixed, paraffin embedded tissue as well as an open-source algorithm (PathML) to rapidly analyze large images and multiple immunofluorescent experiments for spatial transcriptomics.